首页> 外文期刊>Cancer Medicine >Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database
【24h】

Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database

机译:术前放疗可改善可切除的IIIA / N2非小细胞肺癌患者的预后:基于监测,流行病学和最终结果数据库的倾向得分匹配分析

获取原文
           

摘要

Background There are several therapeutic strategies for the management of resectable stage IIIA/N2 non‐small‐cell lung cancer (NSCLC) patients. However, the role of radiotherapy as a preoperative adjuvant therapy is unclear. Methods We retrospectively analyzed the data of stage IIIA/N2 NSCLC patients who either underwent preoperative radiation (PrORT), or did not undergo preoperative radiation, collected from the Surveillance, Epidemiology and End Results (SEER) database, between 2004 and 2013. The primary endpoints were cancer‐specific survival (CSS) and overall survival (OS). Results Ultimately, 493 patients treated with preoperative radiation and 2675 patients treated who were not treated with preoperative radiation, were included in the analysis. Overall, preoperative radiation was associated with a better CSS (HR: 1.427 [1.297‐1.572], P ?=?0.014) and OS (HR: 1.220 [1.131‐1.493], P ?=?0.002) than that observed in patients who did not undergo preoperative radiation. After PSM, preoperative radiation still showed advantage in both CSS and OS. Only age, T stage, and preoperative radiation remained independent prognostic factors for both OS and CSS. In the subgroup analysis, the advantages of preoperative radiotherapy were more pronounced in patients with stage T3 tumors and highly differentiated tumors. Conclusions Preoperative radiation may improve the outcomes of resectable IIIA/N2 NSCLC patients. In IIIA/N2 NSCLC patients, particularly with T3 and highly differentiated tumors, clinicians should boldly apply preoperative radiotherapy to improve the patients' survival.
机译:背景技术有几种治疗可切除的IIIA / N2期非小细胞肺癌(NSCLC)患者的治疗策略。但是,放疗作为术前辅助治疗的作用尚不清楚。方法我们回顾性分析了2004年至2013年间从监测,流行病学和最终结果(SEER)数据库收集的,接受过术前放疗(PrORT)或未接受术前放疗的IIIA / N2期NSCLC患者的数据。终点是癌症特异性生存期(CSS)和总体生存期(OS)。结果最终,分析纳入了493例接受术前放射治疗的患者和2675例未经术前放射治疗的患者。总体而言,术前放疗与患者的CSS(HR:1.427 [1.297-1.572],P?=?0.014)和OS(HR:1.220 [1.131-1.493],P?= 0.002)有较好的相关性。没有接受术前放射。 PSM后,术前放疗在CSS和OS方面仍显示出优势。对于OS和CSS,只有年龄,T分期和术前放疗仍然是独立的预后因素。在亚组分析中,术前放疗的优势在T3期肿瘤和高分化肿瘤患者中更为明显。结论术前放疗可改善可切除的IIIA / N2 NSCLC患者的预后。对于IIIA / N2期NSCLC患者,特别是患有T3和高分化肿瘤的患者,临床医生应大胆应用术前放疗以提高患者的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号